Loading…
Underlying
Underlying Price
$6.01
Type
Put
Strike
15
Expiration
Dec 11, 2026
DTE
28d
Moneyness
ITM
Intrinsic
$8.99
IBRX 15 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | — | — | 0 | 2 |
| Nov 20, 2026 | 7d | — | — | 0 | 0 |
| Nov 27, 2026 | 14d | — | — | 0 | 0 |
| Dec 4, 2026 | 21d | — | — | 0 | 0 |
| Dec 11, 2026 | 28d | — | — | 0 | 0 |
| Dec 18, 2026 | 35d | — | — | 0 | 0 |
| Dec 24, 2026 | 41d | — | — | 0 | 0 |
| Jan 15, 2027 | 63d | $7.70 | +21.84% | 1 | 503 |
| Mar 19, 2027 | 126d | $7.90 | -8.14% | 3 | 5 |
| Apr 16, 2027 | 154d | — | — | 0 | 0 |
| May 21, 2027 | 189d | $8.20 | +7.47% | 1 | 6 |
| Aug 20, 2027 | 280d | $7.80 | +4.00% | 1 | 4 |
| Nov 19, 2027 | 371d | $8.53 | +3.39% | 1 | 2 |
| Jan 21, 2028 | 434d | $8.10 | +2.53% | 65 | 610 |
| Mar 17, 2028 | 490d | $8.50 | -5.56% | 1 | 19 |
| Jan 19, 2029 | 798d | $7.96 | -9.03% | 1 | 8 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.